In short Read article

Direct-acting antiviral agents for chronic hepatitis C


Recent years have seen major progress in the treatment of chronic hepatitis C. New direct-acting antiviral agents (DAAs) have become available in the Netherlands from the end of 2014. Combinations of DAAs against hepatitis C, some of which are active against all phenotypes (pangenotypical), are highly effective in achieving ‘sustained virological response’. There is, however, limited evidence of their effectiveness in terms of reducing morbidity and mortality. Adverse effects of DAAs are minor, but their costs are high.

  • The direct-acting antiviral agents are effective (up to >90%) in terms of achieving a ‘sustained virological response’ (SVR) in hepatitis C. 
  • Reduction of morbidity and mortality by direct-acting antiviral agents has only been shown in observational studies.
  • There are indications that the SVR achieved by DAAs in hepatitis C is associated with a reduction of morbidity and mortality.

  1. Geddawy A, Ibrahim YF, Elbahie NM, Ibrahim MA. Direct Acting Anti-hepatitis C Virus Drugs: Clinical Pharmacology and Future Direction. J Transl Int Med. 2017 Mar 31;5(1):8-17. doi: 10.1515/jtim-2017-0007.
  2. Rijksinstituut voor Volksgezondheid en Milieu. LCI-richtlijn hepatitis C. Available from: https://lci.rivm.nl/richtlijnen/hepatitis-c. Accessed 04-10-2021.
  3. Roudot-Thoraval F. Epidemiology of hepatitis C virus infection. Clin Res Hepatol Gastroenterol. 2021 May;45(3):101596. doi: 10.1016/j.clinre.2020.101596.
  4. Hofman R, Nusselder WJ, Veldhuijzen IK, Richardus JH. Sterfte aan chronische hepatitis B en C in Nederland. Ned Tijdschr Geneeskd. 2016;160:D511.
  5. RIVM. Nationaal hepatitisplan: een strategie voor actie. Publicatiedatum 31-10-2016. Available from: https://www.rivm.nl/nieuws/nationaal-hepatitisplan-strategie-voor-actie. Accessed 24-01-2020.
  6. de Vries MJ, te Rijdt B, van Nieuwkerk CM. Genotype distribution amongst hepatitis C patients in The Netherlands. Neth J Med. 2006 Apr;64(4):109-13.
  7. Zorginstituut Nederland. Farmacotherapeutisch Kompas 2021. Available from: https://www.farmacotherapeutischkompas.nl/. Accessed 04-10-2021.
  8. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C: Final update of the series. J Hepatol. 2020 Nov;73(5):1170-1218. doi: 10.1016/j.jhep.2020.08.018.
  9. Lok AS. Is Sustained Virologic Response to Direct-acting Antivirals a Valid Surrogate Endpoint for Clinical Outcomes of Hepatitis C? Editorial. Clin Infect Dis. 2021 Mar 1;72(5):787-788. doi: 10.1093/cid/ciaa147.
  10. Zoratti MJ, Siddiqua A, Morassut RE, Zeraatkar D, Chou R, van Holten J, et al. Pangenotypic direct acting antivirals for the treatment of chronic hepatitis C virus infection: A systematic literature review and meta-analysis. EClinicalMedicine. 2020 Jan 5;18:100237. doi: 10.1016/j.eclinm.2019.12.007. Geraadpleegd op 29-09-2021.
  11. Carrat F, Fontaine H, Dorival C, Simony M, Diallo A, Hezode C, et al. French ANRS CO22 Hepather cohort. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet. 2019 Apr 6;393(10179):1453-1464. doi: 10.1016/S0140-6736(18)32111-1.
  12. Backus LI, Belperio PS, Shahoumian TA, Mole LA. Direct-acting antiviral sustained virologic response: Impact on mortality in patients without advanced liver disease. Hepatology. 2018 Sep;68(3):827-838. doi: 10.1002/hep.29811.
  13. Informatorium Medicamentorum oktober 2021. Via: KNMP Kennisbank. Geraadpleegd op 04-10-2021.
  14. Dick TB, Lindberg LS, Ramirez DD, Charlton MR. A clinician's guide to drug-drug interactions with direct-acting antiviral agents for the treatment of hepatitis C viral infection. Hepatology. 2016 Feb;63(2):634-43. doi: 10.1002/hep.27920. 
  15. Talavera Pons S, Boyer A, Lamblin G, Chennell P, Châtenet FT, Nicolas C, et al. Managing drug-drug interactions with new direct-acting antiviral agents in chronic hepatitis C. Br J Clin Pharmacol. 2017 Feb;83(2):269-293. doi: 10.1111/bcp.13095.
  16. European Medicines Agency. European Public Assessments Reports. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/epclusa; https://www.ema.europa.eu/en/medicines/human/EPAR/harvoni; https://www.ema.europa.eu/en/medicines/human/EPAR/maviret; https://www.ema.europa.eu/en/medicines/human/EPAR/vosevi; https://www.ema.europa.eu/en/medicines/human/EPAR/zepatier. Accessed 24-12-2021
  17. Z-Index. G-Standaard oktober 2021. Available from: KNMP Kennisbank. Accessed 04-10-2021.
  18. HCV richtsnoer. Available from: https://hcvrichtsnoer.nl/.
  19. Sarrazin C, Isakov V, Svarovskaia ES, Hedskog C, Martin R, Chodavarapu K, et al. Late Relapse Versus Hepatitis C Virus Reinfection in Patients With Sustained Virologic Response After Sofosbuvir-Based Therapies. Clin Infect Dis. 2017 Jan 1;64(1):44-52. doi: 10.1093/cid/ciw676.
  20. World Health Organization. Global health sector strategy on viral hepatitis 2016–2021. Towards ending viral hepatitis. Available from: http://apps.who.int/iris/bitstream/10665/246177/1/WHO-HIV-2016.06-eng.pdf. Accessed 21-01-2022
  21. Calvaruso V, Petta S, Craxì A. Is global elimination of HCV realistic? Liver Int. 2018 Feb;38 Suppl 1:40-46. doi: 10.1111/liv.13668.

Authors

  • Leo M.L. Stolk, dr